CEL Celadon Pharmaceuticals Plc

TIDMCEL

RNS Number : 6209P

Celadon Pharmaceuticals PLC

10 February 2023

Celadon Pharmaceuticals Plc

("Celadon" or the "Company")

Notification of transactions by persons discharging managerial responsibility

London, 10 February 2023 - Celadon Pharmaceuticals Plc (AIM: CEL) , a UK-based pharmaceutical company focused on the research, cultivation, manufacturing and sale of breakthrough cannabis-based medicines, announces that an award of options to acquire the Company's shares for their nominal value of GBP0.01 was granted to an Executive Director on 9 February 2023 under the Company's Long Term Incentive Plan ("LTIP") as shown below. The Options will vest on the third anniversary of grant on 9 February 2026, subject to the achievement of performance criteria. Once vested, the awards must be held for two years.

 
      Details of the person discharging managerial responsibilities 
  1    / person closely associated 
 a)   Name                               Jonathan Turner 
     =================================  =================================== 
      Reason for the notification 
  2 
     ====================================================================== 
 a)   Position / status                  PDMR - Chief Financial Officer 
     =================================  =================================== 
 b)   Initial notification / Amendment   Initial Notification 
     =================================  =================================== 
      Details of the issuer, emission allowance market participant, 
  3    auction platform, auctioneer or auction monitor 
     ====================================================================== 
 a)   Name                               Celadon Pharmaceuticals plc 
     =================================  =================================== 
 b)   LEI                                213800YXCATORT475807 
     =================================  =================================== 
      Details of the transaction(s): section to be repeated for 
  4    (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions have 
       been conducted 
     ====================================================================== 
 a)   Description of the financial       Ordinary shares of GBP0.01 
       instrument, type of instrument     GB00BDQYGP38 
       Identification code 
     =================================  =================================== 
 b)   Nature of the transaction          Award over nominal cost options 
                                          under the Celadon Pharmaceuticals 
                                          plc Long Term Incentive Plan 
     =================================  =================================== 
 c)   Price(s) and volume(s)              Price(s)   Volume(s) 
                                           GBP0.01    347,312 (under 
                                                       the LTIP) 
                                                     =============== 
     =================================  =================================== 
 d)        Aggregated information        N/A Single Transaction 
             *    Aggregated volume 
 
 
             *    Price 
     =================================  =================================== 
 e)   Date of the transaction            9 February 2023 
     =================================  =================================== 
 f)   Place of the transaction           London 
     =================================  =================================== 
 

Enquiries:

 
 Celadon Pharmaceuticals Plc 
 James Short                                    Via Powerscourt 
  Jonathan Turner 
  Arthur Wakeley 
 
 Canaccord Genuity Limited (Nominated 
  Adviser and Broker) 
 Bobbie Hilliam / Andrew Potts / Patrick 
  Dolaghan                                      +44 (0)20 7523 8000 
 
 Powerscourt Group 
 Sarah MacLeod / Nick Johnson / Sam Austrums 
  / 
  Ibrahim Khalil                                +44 (0)20 7250 1446 
 

About Celadon Pharmaceuticals Plc

Celadon Pharmaceuticals Plc is a UK based pharmaceutical company focused on the research, cultivation, manufacturing, and sale of breakthrough cannabis-based medicines. Its primary focus is on improving quality of life for chronic pain sufferers, as well as exploring the potential of cannabis-based medicines for other conditions such as autism. Its 100,000 sq. ft UK facility operates to an EU-GMP standard and comprises indoor hydroponic cultivation, proprietary GMP extraction and manufacturing and an analytical and R&D laboratory. The Company's subsidiary, LVL, owns a MHRA conditionally-approved clinical trial using cannabis based medicinal products to treat chronic pain in the UK. Celadon also has a minority interest in early-stage biopharma Kingdom Therapeutics which is developing a licenced cannabinoid medicine to treat children with Autism Spectrum Disorder.

For further information please visit our website www.celadonpharma.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHFLFISFIIILIV

(END) Dow Jones Newswires

February 10, 2023 09:15 ET (14:15 GMT)

Celadon Pharmaceuticals (LSE:CEL)
Historical Stock Chart
From Jun 2024 to Jul 2024

Celadon Pharmaceuticals (LSE:CEL)
Historical Stock Chart
From Jul 2023 to Jul 2024